| Literature DB >> 35865163 |
Shashank Shekhar Singh1, Bhagwant Rai Mittal1, Ashwani Sood1, Anish Bhattacharya1, Ganesh Kumar1, Amit Singh Shekhawat1, Harpreet Singh1.
Abstract
Purpose This retrospective study aimed to study the applicability of 2015 adult American Thyroid Association (ATA) differentiated thyroid cancer (DTC) postoperative risk stratification and guidelines in the pediatric population for evaluating the number of metastatic lymph nodes in the postoperative risk stratification and postradioactive iodine (RAI) treatment dynamic risk stratification (DRS) using response to treatment (RTT) reclassification. In addition, the effect of pubertal status and gender was assessed on disease presentation and prognosis. Methods Data of 63 DTC patients aged 20 years or less, stratified into prepubertal, pubertal, and postpubertal age groups, was divided into low, intermediate, and high-risk groups using pediatric ATA recurrence risk stratification. Forty-seven patients were classified as responders (excellent and indeterminate responses) and incomplete responders (biochemical and structurally incomplete responses) by assessing the RTT at 1.5 years follow-up similar to recommendation of 2015 adult DTC ATA guidelines. Results Female-to-male ratio showed a trend of gradual increase with increasing age. Significantly more responders were observed in low- and intermediate-risk groups than in high-risk group ( p = 0.0013; p = 0.017, respectively), while prepubertal group had more extensive (N1b) disease. Using DRS at follow-up of 1.5 year, pubertal and postpubertal groups showed significantly better response to RAI. More female than male patients showed response and took significantly less time to respond to RAI ( p = 0.003). Conclusion RAI response in pediatric DTC depends on pubertal status, gender, and number of malignant nodes. DRS using RTT classification may be applicable early at 1.5 years after initial therapy in different pubertal age and risk groups. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: age; children; differentiated thyroid cancer; dynamic risk stratification; puberty; radioactive iodine
Year: 2022 PMID: 35865163 PMCID: PMC9296250 DOI: 10.1055/s-0042-1750334
Source DB: PubMed Journal: World J Nucl Med ISSN: 1450-1147
Criteria for defining the postoperative risk category in pediatric patients of thyroid cancer (adapted from reference 8 )
| Risk category | Definition |
|---|---|
| Low | Disease grossly confined to the thyroid with N0/Nx disease or patients with incidental N1a disease, that is, microscopic metastasis to a small number, that is, ≤5 central neck lymph nodes |
| Intermediate | Extensive (> 5) N1a or minimal (≤ 5) N1b disease |
| High | Regionally extensive disease (> 5 N1b lymph nodes) or locally invasive disease (T4 tumors), with or without distant metastasis |
Clinical, histopathological characteristics of 63 patients with AJCC TNM staging and ATA pediatric DTC risk stratification
|
Total,
|
Prepubertal,
|
Pubertal,
|
Postpubertal,
| ||
|---|---|---|---|---|---|
| Age (Mean ± SD) | 15.2 ± 3.5 | 7.9 ± 1.9 | 13.4 ± 1.5 | 17.6 ± 1.3 | 0.044 |
| Male | 24 (38.1) | 4 (57.2) | 10 (52.6) | 10 (27.1) | 0.099 |
| Female | 39 (61.9) | 3 (42.8) | 9 (47.3) | 27 (72.9) | 0.099 |
| Symptom to first hospital visit (years) | 1.28 | 0.92 | 1.47 | 1.24 | 0.017 |
| Symptoms | |||||
| Neck swelling | 62 (98.4) | 7 (100) | 18(94.7) | 37 (100) | 0.772 |
| Others | 7 | 3 | 1 | 3 | |
| Thyroid surgery | |||||
| Total | 53 (84.1) | 6 (85.7) | 16 (84.2) | 31 (83.8) | 0.992 |
| Hemi + completion | 9 (14.2) | 1 (14.3) | 2 (10.6) | 6 (16.2) | 0.849 |
| No surgery | 1 (0.01) | 0 | 1 (5.2) | 0 | 0.314 |
| Lymph node dissection | |||||
| Central neck | 45 (71.4) | 7 (100) | 15 (78.9) | 23 (62.1) | 0.090 |
| Lateral neck | 38 (60.3) | 6 (85.7) | 12 (63.2) | 20 (54) | 0.284 |
| Unilateral | 15 (39.4) | 1 (16.7) | 5 (41.7) | 9 (45.0) | 0.813 |
| Bilateral | 23 (60.6) | 5 (83.3) | 7 (58.3) | 11 (55.0) | 0.114 |
| Histopathology | |||||
| Classical PTC | 45 (71.4) | 4 (57.1) | 15 (79.0) | 26 (70.3) | 0.540 |
| Follicular variant | 11 (17.5) | 2 (28.6) | 4 (21.0) | 5 (13.6) | 0.562 |
| Tall cell | 2 (3.2) | 1 (14.3) | 0 | 1 (2.7) | 0.182 |
| Follicular | 2 (3.2) | 0 | 0 | 2 (5.4) | 0.490 |
| Others | 3 (4.7) | 0 | 0 | 3 (8.0) | 0.336 |
|
T stage (
| |||||
| T1 | 16 (31.4) | 3 (42.8) | 6 (35.3) | 7 (26.0) | 0.318 |
| T2 | 20 (39.2) | 4 (51.2) | 4 (23.5) | 12 (44.4) | 0.218 |
| T3 | 11 (21.6) | 0 | 5 (29.5) | 6 (22.2) | 0.285 |
| T4 | 4 (7.8) | 0 | 2 (11.7) | 2 (7.4) | 0.586 |
|
N stage (
| |||||
| NX | 4 (7.3) | 0 | 1 (5.3) | 3 (10.3) | 0.707 |
| N0 | 3 (5.5) | 0 | 0 | 3 (10.3) | 0.336 |
| N1A | 12 (21.8) | 1 (14.3) | 4 (21.0) | 7 (24.2) | 0.928 |
| N1B | 36 (65.4) | 6 (85.7) | 14 (73.7) | 16 (55.2) | 0.027 |
|
M stage (
| |||||
| M0 | 47 (74.6) | 2 (28.6) | 12 (63.2) | 33 (89.2 | 0.034 |
| M1 | 16 (25.4) | 5 (71.4) | 7 (36.8) | 4 (10.8) | 0.034 |
| Lungs | 16 | 5 | 7 | 4 | 0.034 |
| Bones | 0 | 0 | 0 | 0 | |
|
ATA recurrence risk (
| |||||
| Low | 8 (14.3) | 0 | 0 | 8 (26.6) | 0.042 |
| Intermediate | 18 (32.1) | 2 (28.6) | 5 (26.4) | 11 (36.7) | 0.965 |
| High | 30 (53.6) | 5 (71.4) | 14 (73.6) | 11 (36.7) | 0.003 |
Abbreviations: AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; DTC, differentiated thyroid cancer; PTC, papillary thyroid cancer; SD, standard deviation; TNM, tumor node metastasis.
Summary of radioactive iodine treatment in different pubertal age groups
| Follow-up data |
Total,
|
Prepubertal,
| Pubertal |
Postpubertal,
|
|---|---|---|---|---|
| Follow-up duration (mo) | ||||
| Mean | 46.3 (18–102) | 35.2 (18–74) | 48.5 (21–102) | 48.3 (18–96) |
| Radioactive iodine treatment | ||||
| Received | 46 | 7 | 12 | 27 |
| Not received | 1 | – | – | 1 |
| Number of I-131 doses: | ||||
| Single dose | 21 | 1 (14) | 4 (33) | 16 (59) |
| Two doses | 5 | 1 (14) | 1 (8) | 3 (11) |
| ≥ 3 doses | 20 | 5 (71) | 7 (58) | 8 (30) |
| Average cumulative dose (MBq) | 9,879 | 12,606 | 12,595 | 7,992 |
| Risk category | ||||
| High | 27 (57) | 6 (86) | 8 (67) | 13 (46) |
| Intermediate | 14 (30) | 1 (14) | 4 (33) | 9 (32) |
| Low | 6 (13) | 0 | 0 | 6 (22) |
| Responders | 24 (51) | 0 | 7 (58) | 17 (61) |
| Nonresponders | 23 (49) | 7 (100) | 5 (42) | 11 (39) |
Fig. 1Response to radioactive iodine treatment for different metastatic sites assessed at 1.5-year in post-treatment follow-up diagnostic whole-body scan in overall and different pediatric age groups.
Responders in different pubertal status according to risk categories at follow-up of 1.5 years ( n = 24)
| Prepubertal (0) | Pubertal (7) | Postpubertal (17) | |
|---|---|---|---|
|
Low-risk category (
| – | – | 6 |
|
Intermediate-risk category (
| 0 | 3 | 6 |
|
High-risk category (
| 0 | 4 | 5 |
(–) since there were no prepubertal and pubertal patients in low-risk category.
Fig. 2Probability of incomplete responders to radioactive iodine at subsequent follow-ups in different pubertal age groups. Prepubertal and pubertal groups showed significantly higher rate of incomplete responders compared with postpubertal group. Blue line : prepubertal age group, pink line : pubertal age group, green line : postpubertal age group.
Fig. 3Probability of incomplete responders to radioactive iodine at subsequent follow-ups in males and females. Follow-up showed more females were responders and shorter time taken to response compared with males. Blue line : females, pink line : males.